Potential of gene therapy as a treatment for heart failure

Journal of Clinical Investigation

Volumn 123, Issue 1, 2013, Pages 53-61

  Hajjar, Roger J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ADENOVIRUS VECTOR; BETA ADRENERGIC RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; LENTIVIRUS VECTOR; PARVOVIRUS VECTOR; PHOSPHOLAMBAN; RETROVIRUS VECTOR; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SUMO 1 PROTEIN; SUMO PROTEIN;

ARTERY CATHETERIZATION; CARDIAC PATIENT; CARDIOVASCULAR GENE THERAPY; DRUG MEGADOSE; ENDOPLASMIC RETICULUM; GENE TARGETING; GENE TRANSFER; GENE VECTOR; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE INJURY; HUMAN; INTRAVASCULAR ULTRASOUND; LEFT VENTRICULAR ASSIST DEVICE; LOW DRUG DOSE; MICROBUBBLE; MOLECULARLY TARGETED THERAPY; NONHUMAN; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; SARCOPLASMIC RETICULUM; TARGET CELL; TARGET ORGAN; TRANSGENE; VEIN CATHETERIZATION;

GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HEART FAILURE; MUSCLE PROTEINS; MYOCARDIUM; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES;

EID: 84873864178     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI62837     Document Type: Review

References (88)

1. Roger VL, et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2-e220.
2. Tilemann L, Ishikawa K, Weber T, Hajjar RJ. Gene therapy for heart failure. Circ Res. 2012; 110(5): 777-793.
3. Trono D. Lentiviral vectors: turning a deadly foe into a therapeutic agent. Gene Ther. 2000;7(1): 20-23.
4. Bonci D, et al. 'Advanced' generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo. Gene Ther. 2003; 10(8): 630-636.
5. Vetrini F, Ng P. Gene therapy with helper-dependent adenoviral vectors: current advances and future perspectives. Viruses. 2010;2(9): 1886-1917.
6. Giordano FJ, et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med. 1996;2(5): 534-539.
7. Asokan A, Schaffer DV, Samulski RJ. The AAV vector toolkit: poised at the clinical crossroads. Mol Ther. 2012;20(4): 699-708.
8. Li C, et al. Neutralizing antibodies against adenoassociated virus examined prospectively in pediatric patients with hemophilia. Gene Ther. 2012; 19(3): 288-294.
9. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis. 2009;199(3): 381-390.
10. Ladage D, Ishikawa K, Tilemann L, Muller-Ehmsen J, Kawase Y. Percutaneous methods of vector delivery in preclinical models. Gene Ther. 2012; 19(6): 637-641.
11. Ishikawa K, et al. Cardiac gene therapy in large animals: bridge from bench to bedside. Gene Ther. 2012; 19(6): 670-677.
12. Parsa CJ, et al. Catheter-mediated subselective intracoronary gene delivery to the rabbit heart: introduction of a novel method. J Gene Med. 2005; 7(5): 595-603.
13. Hayase M, et al. Catheter-based antegrade intracoronary viral gene delivery with coronary venous blockade. Am J Physiol Heart Circ Physiol. 2005; 288(6):H2995-H3000.
14. Beeri R, et al. Gene delivery of sarcoplasmic reticulum calcium ATPase inhibits ventricular remodeling in ischemic mitral regurgitation. Circ Heart Fail. 2010;3(5): 627-634.
15. Kaye DM, et al. Percutaneous cardiac recirculationmediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals. J Am Coll Cardiol. 2007;50(3): 253-260.
16. Byrne MJ, Power JM, Preovolos A, Mariani JA, Hajjar RJ, Kaye DM. Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Ther. 2008;15(23): 1550-1557.
17. Mariani JA, Smolic A, Preovolos A, Byrne MJ, Power JM, Kaye DM. Augmentation of left ventricular mechanics by recirculation-mediated AAV2/1-SERCA2a gene delivery in experimental heart failure. Eur J Heart Fail. 2011;13(3): 247-253.
18. Sasano T, Kikuchi K, McDonald AD, Lai S, Donahue JK. Targeted high-efficiency, homogeneous myocardial gene transfer. J Mol Cell Cardiol. 2007; 42(5): 954-961.
19. Donahue JK, Kikkawa K, Johns DC, Marban E, Lawrence JH. Ultrarapid, highly efficient viral gene transfer to the heart. Proc Natl Acad Sci U S A. 1997;94(9): 4664-4668.
20. Ladage D, et al. Increasing the efficacy of myocardial gene therapy with an intra-aortic balloon pump in a large animal model of heart failure. Eur Heart J. 2011;32(abstract supplement):814.
21. Ryden L, et al. Pharmacokinetic analysis of coronary venous retroinfusion: a comparison with anterograde coronary artery drug administration using metoprolol as a tracer. J Am Coll Cardiol. 1991; 18(2): 603-612.
22. Karagueuzian HS, et al. Coronary venous retroinfusion of procainamide: a new approach for the management of spontaneous and inducible sustained ventricular tachycardia during myocardial infarction. J Am Coll Cardiol. 1986;7(3): 551-563.
23. Su LT, et al. Uniform scale-independent gene transfer to striated muscle after transvenular extravasation of vector. Circulation. 2005;112(12): 1780-1788.
24. Boekstegers P, et al. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins. Gene Ther. 2000;7(3): 232-240.
25. Raake P, et al. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins: comparison with surgical and percutaneous intramyocardial gene delivery. J Am Coll Cardiol. 2004; 44(5): 1124-1129.
26. Hou D, et al. Widespread regional myocardial transfection by plasmid encoding Del-1 following retrograde coronary venous delivery. Catheter Cardiovasc Interv. 2003;58(2): 207-211.
27. Davidson MJ, et al. Cardiac gene delivery with cardiopulmonary bypass. Circulation. 2001; 104(2): 131-133.
28. White JD, et al. Myocardial gene delivery using molecular cardiac surgery with recombinant adenoassociated virus vectors in vivo. Gene Ther. 2011; 18(6): 546-552.
29. Grossman PM, Han Z, Palasis M, Barry JJ, Lederman RJ. Incomplete retention after direct myocardial injection. Catheter Cardiovasc Interv. 2002; 55(3): 392-397.
30. Bish LT, et al. Percutaneous transendocardial delivery of self-complementary adeno-associated virus 6 achieves global cardiac gene transfer in canines. Mol Ther. 2008;16(12): 1953-1959.
31. French BA, Mazur W, Geske RS, Bolli R. Direct in vivo gene transfer into porcine myocardium using replication-deficient adenoviral vectors. Circulation. 1994;90(5): 2414-2424.
32. Gepstein L, Hayam G, Ben-Haim SA. A novel method for nonfluoroscopic catheter-based electroanatomical mapping of the heart. In vitro and in vivo accuracy results. Circulation. 1997;95(6): 1611-1622.
33. Sanborn TA, et al. Percutaneous endocardial transfer and expression of genes to the myocardium utilizing fluoroscopic guidance. Catheter Cardiovasc Interv. 2001;52(2): 260-266.
34. Baklanov DV, et al. Live 3D echo guidance of catheter-based endomyocardial injection. Catheter Cardiovasc Interv. 2005;65(3): 340-345.
35. Lederman RJ, et al. Catheter-based endomyocardial injection with real-time magnetic resonance imaging. Circulation. 2002;105(11): 1282-1284.
36. Fromes Y, et al. Gene delivery to the myocardium by intrapericardial injection. Gene Ther. 1999; 6(4): 683-688.
37. Waxman S, Moreno R, Rowe KA, Verrier RL. Persistent primary coronary dilation induced by transatrial delivery of nitroglycerin into the pericardial space: a novel approach for local cardiac drug delivery. J Am Coll Cardiol. 1999;33(7): 2073-2077.
38. Lamping KG, Rios CD, Chun JA, Ooboshi H, Davidson BL, Heistad DD. Intrapericardial administration of adenovirus for gene transfer. Am J Physiol. 1997;272(1 pt 2):H310-H317.
39. Ladage D, et al. Delivery of gelfoam-enabled cells and vectors into the pericardial space using a percutaneous approach in a porcine model. Gene Ther. 2011; 18(10): 979-985.
40. Roques C, Salmon A, Fiszman MY, Fattal E, Fromes Y. Intrapericardial administration of novel DNA formulations based on thermosensitive Poloxamer 407 gel. Int J Pharm. 2007;331(2): 220-223.
41. Boulanger B, Yuan Z, Flessner M, Hay J, Johnston M. Pericardial fluid absorption into lymphatic vessels in sheep. Microvasc Res. 1999;57(2): 174-186.
42. Ladage D, et al. Delivery of gelfoam-enabled cells and vectors into the pericardial space using a percutaneous approach in a porcine model. Gene Ther. 2011; 18(10): 979-985.
43. Shohet RV, Grayburn PA. Potential bioeffects of ultrasonic destruction of microbubble contrast agents. J Am Coll Cardiol. 2006;47(7): 1469-1470.
44. Beeri R, Guerrero JL, Supple G, Sullivan S, Levine RA, Hajjar RJ. New efficient catheter-based system for myocardial gene delivery. Circulation. 2002; 106(14): 1756-1759.
45. Engelhardt S, Hein L, Dyachenkow V, Kranias EG, Isenberg G, Lohse MJ. Altered calcium handling is critically involved in the cardiotoxic effects of chronic beta-adrenergic stimulation. Circulation. 2004;109(9): 1154-1160.
46. Milano CA, et al. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. Science. 1994;264(5158): 582-586.
47. Maurice JP, et al. Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary beta2-adrenergic receptor gene delivery. J Clin Invest. 1999;104(1): 21-29.
48. Shah AS, et al. Intracoronary adenovirus-mediated delivery and overexpression of the beta(2)- adrenergic receptor in the heart: prospects for molecular ventricular assistance. Circulation. 2000; 101(4): 408-414.
49. Hata JA, Williams ML, Koch WJ. Genetic manipulation of myocardial beta-adrenergic receptor activation and desensitization. J Mol Cell Cardiol. 2004; 37(1): 11-21.
50. Raake PW, et al. G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ Res. 2008; 103(4): 413-422.
51. Shah AS, et al. In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation. 2001;103(9): 1311-1316.
52. Katz MG, et al. AAV6-betaARKct gene delivery mediated by molecular cardiac surgery with recirculating delivery (MCARD) in sheep results in robust gene expression and increased adrenergic reserve. J Thorac Cardiovasc Surg. 2012;143(3): 720-726.
53. Gao MH, et al. Adenylylcyclase increases responsiveness to catecholamine stimulation in transgenic mice. Circulation. 1999;99(12): 1618-1622.
54. Lai NC, et al. Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure. Circulation. 2004;110(3): 330-336.
55. Lai NC, et al. Intracoronary delivery of adenovirus encoding adenylyl cyclase VI increases left ventricular function and cAMP-generating capacity. Circulation. 2000;102(19): 2396-2401.
56. Gwathmey JK, et al. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res. 1987;61(1): 70-76.
57. Hasenfuss G, et al. Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium. Circ Res. 1994;75(3): 434-442.
58. Meyer M, et al. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation. 1995;92(4): 778-784.
59. Schmidt U, Hajjar RJ, Kim CS, Lebeche D, Doye AA, Gwathmey JK. Human heart failure: cAMP stimulation of SR Ca(2+)-ATPase activity and phosphorylation level of phospholamban. Am J Physiol. 1999;277(2 pt 2):H474-H480.
60. Lompre AM, Lambert F, Lakatta EG, Schwartz K. Expression of sarcoplasmic reticulum Ca(2+)- ATPase and calsequestrin genes in rat heart during ontogenic development and aging. Circ Res. 1991; 69(5): 1380-1388.
61. Miyamoto MI, et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci U S A. 2000;97(2): 793-798.
62. del Monte F, et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation. 1999;100(23): 2308-2311.
63. Kawase Y, et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol. 2008;51(11): 1112-1119.
64. Sakata S, et al. Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins. J Mol Cell Cardiol. 2007;42(4): 852-861.
65. Sakata S, et al. Transcoronary gene transfer of SERCA2a increases coronary blood flow and decreases cardiomyocyte size in a type 2 diabetic rat model. Am J Physiol Heart Circ Physiol. 2007;292(2):H1204-H1207.
66. Lyon AR, et al. SERCA2a gene transfer decreases sarcoplasmic reticulum calcium leak and reduces ventricular arrhythmias in a model of chronic heart failure. Circ Arrhythm Electrophysiol. 2011;4(3): 362-372.
67. Cutler MJ, Wan X, Laurita KR, Hajjar RJ, Rosenbaum DS. Targeted SERCA2a gene expression identifies molecular mechanism and therapeutic target for arrhythmogenic cardiac alternans. Circ Arrhythm Electrophysiol. 2009;2(6): 686-694.
68. del Monte F, et al. Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling. Proc Natl Acad Sci U S A. 2004;101(15): 5622-5627.
69. Prunier F, et al. Prevention of ventricular arrhythmias with sarcoplasmic reticulum Ca2+ ATPase pump overexpression in a porcine model of ischemia reperfusion. Circulation. 2008;118(6): 614-624.
70. Hadri L, et al. SERCA2a gene transfer enhances eNOS expression and activity in endothelial cells. Mol Ther. 2010;18(7): 1284-1292.
71. del Monte F, Harding SE, Dec GW, Gwathmey JK, Hajjar RJ. Targeting phospholamban by gene transfer in human heart failure. Circulation. 2002; 105(8): 904-907.
72. Suckau L, et al. Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation. 2009;119(9): 1241-1252.
73. Nicolaou P, et al. Inducible expression of active protein phosphatase-1 inhibitor-1 enhances basal cardiac function and protects against ischemia/reperfusion injury. Circ Res. 2009;104(8): 1012-1020.
74. Pathak A, Baldwin B, Kranias EG. Key protein alterations associated with hyperdynamic cardiac function: insights based on proteomic analysis of the protein phosphatase 1 inhibitor-1 overexpressing hearts. Hellenic J Cardiol. 2007;48(1): 30-36.
75. Pathak A, et al. Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res. 2005; 96(7): 756-766.
76. Most P, et al. Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J Clin Invest. 2004; 114(11): 1550-1563.
77. Pleger ST, et al. Stable myocardial-specific AAV6- S100A1 gene therapy results in chronic functional heart failure rescue. Circulation. 2007; 115(19): 2506-2515.
78. Most P, Koch WJ. S100A1: a calcium-modulating inotropic prototype for future clinical heart failure therapy. Future Cardiol. 2007;3(1): 5-11.
79. Kho C, et al. SUMO1-dependent modulation of SERCA2a in heart failure. Nature. 2011; 477(7366): 601-605.
80. Ghadge SK, Muhlstedt S, Ozcelik C, Bader M. SDF-1alpha as a therapeutic stem cell homing factor in myocardial infarction. Pharmacol Ther. 2011; 129(1): 97-108.
81. Kawase Y, Ladage D, Hajjar RJ. Rescuing the failing heart by targeted gene transfer. J Am Coll Cardiol. 2011;57(10): 1169-1180.
82. Pyo RT, et al. CXCR4 modulates contractility in adult cardiac myocytes. J Mol Cell Cardiol. 2006; 41(5): 834-844.
83. Chen J, et al. Effects of CXCR4 gene transfer on cardiac function after ischemia-reperfusion injury. Am J Pathol. 2010;176(4): 1705-1715.
84. LaRocca TJ, et al. beta2-Adrenergic receptor signaling in the cardiac myocyte is modulated by interactions with CXCR4. J Cardiovasc Pharmacol. 2010;56(5): 548-559.
85. Bainbridge JW, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med. 2008;358(21): 2231-2239.
86. Hajjar RJ, et al. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail. 2008; 14(5): 355-367.
87. Jaski BE, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail. 2009;15(3): 171-181.
88. Jessup M, et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+- ATPase in patients with advanced heart failure. Circulation. 2011;124(3): 304-313.